Assessment Of Lipid Profile In Cirrhotic Patients
1 other identifier
observational
100
1 country
1
Brief Summary
Cirrhosis is defined anatomically as a diffuse process with fibrosis and nodule formation. It is the result of the fibrogenesis that occurs with chronic liver injury. Lipoproteins are complexes of lipid and proteins that are essential for transport of soluble vitamins Liver cells play a serious task in the regulation of lipid metabolism. The principal location for lipoprotein and cholesterol synthesis is in the liver. In healthy individuals, a compound equilibrium is preserved between utilization, biosynthesis, and transfer of lipid fractions. Many diseases that affect the parenchyma can lead to changes in the structure of lipoproteins and transport throughout the blood. Nevertheless, in cirrhotic patients, the metabolism of lipid is changed such that glycogen stores are significantly diminished, contributing to malnutrition and biolysis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Mar 2021
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 1, 2021
CompletedStudy Start
First participant enrolled
March 1, 2021
CompletedFirst Posted
Study publicly available on registry
March 9, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2021
CompletedMay 19, 2022
February 1, 2021
6 months
March 1, 2021
May 12, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Measurement of the lipid profile in cirrhotic patients and compare its levels with normal persons.
Via measurement the levels of triglyceride (TG), total cholesterol,very low-density lipoprotein, low density lipoprotien (LDH), and high-density lipoprotien (HDL) in cirrhotic patients and compare with the control.
15 weeks from start point.
Secondary Outcomes (1)
Measurement the degree of liver cirrhosis severity and its relationship to lipid profile levels.
15 weeks from start point
Eligibility Criteria
Patients with liver cirrhosis. Diagnosis of liver cirrhosis depend on clinical, laboratory, and radiological finding.
You may qualify if:
- Cirrhotic patients .
You may not qualify if:
- Patients with diabetes mellitus,malignancy,uremia. 2-Patients with history of drugs for dyslipidemia. 3- Patients presented with hepatocellular carcinoma 4- Wilsons disease. 5-Rheumatoid arthritis. 6- Systemic lupus.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sohag Universitylead
Study Sites (1)
Sohag University
Sohag, 093, Egypt
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Resident in Tropical Medicine and Gastroenterology Department
Study Record Dates
First Submitted
March 1, 2021
First Posted
March 9, 2021
Study Start
March 1, 2021
Primary Completion
September 1, 2021
Study Completion
September 1, 2021
Last Updated
May 19, 2022
Record last verified: 2021-02